HomeCompareBPAIF vs ABBV

BPAIF vs ABBV: Dividend Comparison 2026

BPAIF yields 20000.00% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BPAIF wins by $52481917574412746752.00M in total portfolio value
10 years
BPAIF
BPAIF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full BPAIF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — BPAIF vs ABBV

📍 BPAIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPAIFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPAIF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPAIF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPAIF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, BPAIF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPAIF + ABBV for your $10,000?

BPAIF: 50%ABBV: 50%
100% ABBV50/50100% BPAIF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BPAIF
No analyst data
Altman Z
-83.5
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPAIF buys
0
ABBV buys
0
No recent congressional trades found for BPAIF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPAIFABBV
Forward yield20000.00%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$52481917574412746752.00M$103.7K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$25,324.79
Total dividends collected$52448189483771600896.00M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BPAIF vs ABBV ($10,000, DRIP)

YearBPAIF PortfolioBPAIF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,555$434.96+$2.00MBPAIF
2$377,983,225$375,831,775.70$13,485$635.47+$377.97MBPAIF
3$66,433,479,469$66,029,037,418.28$15,933$937.67+$66433.46MBPAIF
4$10,916,985,471,987$10,845,901,648,955.73$19,118$1,400.80+$10916985.45MBPAIF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$23,384$2,125.24+$1677384363.75MBPAIF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$29,290$3,286.81+$240985175079.11MBPAIF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$37,776$5,205.38+$32373573631143.66MBPAIF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$50,495$8,488.44+$4066766648320630.00MBPAIF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$70,497$14,346.44+$477730483406513344.00MBPAIF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$103,718$25,324.79+$52481917574412746752.00MBPAIF

BPAIF vs ABBV: Complete Analysis 2026

BPAIFStock

BrandPilot AI Inc., a digital advertising technology company specializing in AI-driven performance marketing in Canada. The company offers Software-as-a-Service (SaaS) platforms leveraging machine learning and automation; and AdAi that enables brands to reduce spending on branded search which integrates with Performance Max, Dynamic Search Ads, Shopping Ads, SA360, and Smart Bidding campaigns. It also offers Spectrum IQ, an AI-powered influencer marketing platform that helps brands scale engagement by activating micro-influencers across Instagram, Facebook, TikTok, LinkedIn, YouTube, and Twitch and connects directly with Shopify and WooCommerce; and Social Runway, a social media management tool designed for agencies and marketers, enabling bulk content creation, scheduling, approvals, and inbox. The company was formerly known as Universal PropTech Inc. and changed its name to BrandPilot AI Inc. in June 2024. The company is headquartered in Toronto, Canada.

Full BPAIF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BPAIF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPAIF vs SCHDBPAIF vs JEPIBPAIF vs OBPAIF vs KOBPAIF vs MAINBPAIF vs JNJBPAIF vs MRKBPAIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.